Prostate-specific membrane antigen (PSMA) has emerged as an ideal biomarker for targeted radionuclide therapy (TRT) and imaging in nuclear medicine, particularly for diagnosing and treating prostate cancer. Here, FOLH1 is linked to prostate cancer.